Palabras claves: Bioreductive compounds, cancer-treatment resistance, carbonic anhydrase inhibitors, dual-activity compounds, non-invasive oxygen detection, targets for new treatment
Autores: Ahmed A., Alsner J., Ashcroft M., Buffa F.M., Busk M., Calzada M.J., Cao Y., Chiche J., Cojocari D., Dubois L., Ebbesen P., Flamm H., Flatmark K., Gieling R.G., Görlach A., Haider S., Harris A.L., Jobst G., Kieninger J., Koritzinsky M., Kunkler I.H., Lambin P., Langdon S.P., Lyng H., Manuel Ortiz de Landázuri, Marchiq I., Mazure N., Meehan J., Moser I., Mujcic H., Overgaard J., Parks S., Pastorekova S., Peso L.D., Pettersen E.O., Pouyssegur J., Ree A.H., Rouschop K.M., Scozzafava A., Singleton D.C., Supuran C.T., Toustrup K., Urban G., Ward C., Weltin A., Williams K.J., Wouters B.G.
